Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy - UpToDate
uptodate.com · 347 words · saved by 1 readers
{{configCtrl2.metaDescription()}}
Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy Authors:Shilpa Grover, MD, MPH, AGAFYinghong Wang, MD, PhDMichael Dougan, MD, PhDStephen D Zucker, MD Section Editors:Michael B Atkins, MDKeith D Lindor, MDSunanda V Kane, MD, MSPH Deputy Editor:Sonali M Shah, MD Literature review current through: Aug 2026. This topic last updated: Jan 09, 2026. INTRODUCTION With the widespread use of immune checkpoint inhibitors (ICI; also known as checkpoint inhibitor immunotherapy) for treatment of various types of cancer, immune-related adverse events…
related reading
- UpToDateuptodate.com
- Overview of toxicities associated with immune checkpoint inhibitorsuptodate.com
- Immunotherapy for Cancer - NCIcancer.gov
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
- Pancreatic Cancer - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- Faecal transplants can treat some cancers — but probably won’t ever be widely usednature.com
- Clinical presentation, diagnosis, and staging of pancreatic neuroendocrine neoplasmsuptodate.com
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanomanature.com
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- UpToDateuptodate.com
- Weekly Dose of Optimism #208notboring.co